Drug Profile


Alternative Names: [14C]Lorlatinib; [14C]PF-06463922; PF-06463922; PF-6463922

Latest Information Update: 24 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer New Approaches to Neuroblastoma Therapy Consortium; Pfizer; The EVAN Foundation; University of Southern California
  • Class Antineoplastics; Aza compounds; Benzoxazines; Nitriles; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Neuroblastoma

Most Recent Events

  • 20 Oct 2017 Pfizer initiates an expanded access for Non small cell lung cancer (Late stage disease) in USA, before October 2017 (NCT03178071)
  • 16 Oct 2017 Final efficacy and adverse events data from phase II portion of a phase I/II trial in Non-small cell lung cancer presented at the 18th World Conference on Lung Cancer (WCLC-2017)
  • 01 Sep 2017 Phase-I clinical trials in Neuroblastoma (Combination therapy, In adolescents, In adults, In children, In infants, In the elderly, Second-line therapy or greater) in Canada, USA (PO) (NCT03107988)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top